Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023-12 · 21 (12) · 1281-1301
DOI: 10.6004/jnccn.2023.0061 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023-12. Verfasst von Shaji K Kumar und 34 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mayo Clinic Comprehensive Cancer Center.
- University of Wisconsin Carbone Cancer Center.
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
- UT Southwestern Simmons Comprehensive Cancer Center.
- Vanderbilt-Ingram Cancer Center.
- Moffitt Cancer Center.
Zitieren
APA
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Hultcrantz, M., …, & Snedeker, J. (2023). Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 21(12), 1281-1301. https://doi.org/10.6004/jnccn.2023.0061
Vancouver
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2023;21(12):1281-1301. doi:10.6004/jnccn.2023.0061
BibTeX
@article{Kumar2023,
author = {Kumar, Shaji K and Callander, Natalie S and Adekola, Kehinde and Anderson, Larry D and Baljevic, Muhamed and Baz, Rachid and Campagnaro, Erica and Castillo, Jorge J and Costello, Caitlin and D'Angelo, Christopher and Devarakonda, Srinivas and Elsedawy, Noura and Garfall, Alfred and Godby, Kelly and Hillengass, Jens and Holmberg, Leona and Htut, Myo and Huff, Carol Ann and Hultcrantz, Malin and Kang, Yubin and Larson, Sarah and Lee, Hans C and Liedtke, Michaela and Martin, Thomas and Omel, James and Robinson, Timothy and Rosenberg, Aaron and Sborov, Douglas and Schroeder, Mark A and Sherbenou, Daniel and Suvannasankha, Attaya and Valent, Jason and Varshavsky-Yanovsky, Asya Nina and Kumar, Rashmi and Snedeker, Jenna},
title = {Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
volume = {21},
number = {12},
pages = {1281--1301},
doi = {10.6004/jnccn.2023.0061}
}
EUVIMED